Gentian Diagnostics AS (OSL:GENT) Cyclically Adjusted Revenue per Share: kr6.98 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:GENT Gentian Diagnostics AS OSL:GENT
73 GF Score
Price kr40.20
GF Value kr59.23
Valuation Significantly Undervalued
View Full Analysis

What is Gentian Diagnostics AS Cyclically Adjusted Revenue per Share?

Gentian Diagnostics AS OSL:GENT +5.24% 73 Cyclically Adjusted Revenue per Share is kr6.98 as of Jun. 2026. GuruFocus rates OSL:GENT with a GF Score™ of 73/100 and a GF Value™ of kr59.23 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gentian Diagnostics AS's adjusted revenue per share for the three months ended in Jun. 2026 was kr3.221. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr6.98 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Gentian Diagnostics AS's average Cyclically Adjusted Revenue Growth Rate was 16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-19), Gentian Diagnostics AS's current stock price is kr40.20. Gentian Diagnostics AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was kr6.98. Gentian Diagnostics AS's Cyclically Adjusted PS Ratio of today is 5.76.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gentian Diagnostics AS was 10.97. The lowest was 5.25. And the median was 8.66.


Gentian Diagnostics AS  (OSL:GENT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gentian Diagnostics AS's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=40.20/6.98
=5.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gentian Diagnostics AS was 10.97. The lowest was 5.25. And the median was 8.66.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gentian Diagnostics AS Cyclically Adjusted Revenue per Share Related Terms


Gentian Diagnostics AS Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS Cyclically Adjusted Revenue per Share Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 5.56 6.43

Gentian Diagnostics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.97 6.21 6.43 6.72 6.98

OSL:GENT vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Cyclically Adjusted PS Ratio falls into.


OSL:GENT
73GF Score
Gentian Diagnostics AS OSL:GENT
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gentian Diagnostics AS's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.221/141.8500*141.8500
=3.221

Current CPI (Jun. 2026) = 141.8500.

Gentian Diagnostics AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.463 104.200 0.630
201612 1.015 104.400 1.379
201703 0.394 105.000 0.532
201706 0.669 105.800 0.897
201709 0.520 105.900 0.697
201712 0.414 106.100 0.553
201803 0.804 107.300 1.063
201806 0.711 108.500 0.930
201809 1.196 109.500 1.549
201812 0.358 109.800 0.462
201903 0.784 110.400 1.007
201906 0.787 110.600 1.009
201909 0.953 111.100 1.217
201912 0.591 111.300 0.753
202003 1.242 111.200 1.584
202006 1.080 112.100 1.367
202009 0.860 112.900 1.081
202012 1.158 112.900 1.455
202103 1.274 114.600 1.577
202106 1.594 115.300 1.961
202109 1.115 117.500 1.346
202112 1.409 118.900 1.681
202203 1.333 119.800 1.578
202206 1.951 122.600 2.257
202209 1.496 125.600 1.690
202212 1.810 125.900 2.039
202303 2.038 127.600 2.266
202306 2.216 130.400 2.411
202309 2.079 129.800 2.272
202312 2.429 131.900 2.612
202403 2.497 132.600 2.671
202406 2.427 133.800 2.573
202409 2.014 133.700 2.137
202412 2.703 134.800 2.844
202503 2.823 136.100 2.942
202506 2.825 137.800 2.908
202509 2.697 138.500 2.762
202512 3.004 139.100 3.063
202603 2.843 141.030 2.860
202606 3.221 141.850 3.221

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr6.98 mean?
Gentian Diagnostics AS (OSL:GENT) has a Cyclically Adjusted Revenue per Share of kr6.98 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gentian Diagnostics AS and its competitors.
Is Gentian Diagnostics AS's Cyclically Adjusted Revenue per Share too high?
Gentian Diagnostics AS's current Cyclically Adjusted Revenue per Share is kr6.98. Overall, Gentian Diagnostics AS has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gentian Diagnostics AS's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Gentian Diagnostics AS's Cyclically Adjusted Revenue per Share of kr6.98 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gentian Diagnostics AS and its competitors. Gentian Diagnostics AS's current Cyclically Adjusted Revenue per Share is kr6.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gentian Diagnostics AS stock overvalued right now?
Based on GuruFocus' analysis, Gentian Diagnostics AS (OSL:GENT) is currently considered Significantly Undervalued. The stock's GF Value™ is kr59.23, compared to a current price of kr40.20 — trading 32.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr6.98. Gentian Diagnostics AS's overall GF Score™ is 73/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Gentian Diagnostics AS (OSL:GENT), the current Cyclically Adjusted Revenue per Share is kr6.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr40.20 is trading 32.1% below its estimated GF Value™ of kr59.23. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for OSL:GENT:

  • Cyclically Adjusted Revenue per Share: kr6.98
  • GF Value™: kr59.23 vs. price of kr40.20 (32.1% below fair value)
  • GF Score™: 73/100

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
73GF Score

Get the complete analysis for OSL:GENT

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr40.20
Price
kr59.23
GF Value